BPG is committed to discovery and dissemination of knowledge
Basic Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. Nov 26, 2026; 18(11): 124181
Published online Nov 26, 2026. doi: 10.4330/wjc.124181
Xin-II shows cardioprotective effects in a rat model of chronic heart failure: An integrated network pharmacology and transcriptomic
Xi-Ju Liu, Yan Cong, Ran Zheng, Ming Li, Zhi Xiu, School of Clinical Medicine, Inner Mongolia Minzu University, Tongliao 028000, Inner Mongolia Autonomous Region, China
Peng-Fei Hu, Guo-Hua Wu, Cha-Gan Lianhua, Quan Wan, Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Minzu University, TongLiao 028000, Inner Mongolia Autonomous Region, China
ORCID number: Peng-Fei Hu (0009-0006-3885-5399); Quan Wan (0000-0002-2603-3092).
Co-corresponding authors: Cha-Gan Lianhua and Quan Wan.
Author contributions: Liu XJ was instrumental and responsible for data re-analysis and re-interpretation, figure plotting, comprehensive literature search, preparation and submission of the current version of the manuscript; Liu XJ and Lianhua CG contributed to formal analysis; Liu XJ and Wan Q contributed to conducting the research, and writing original draft; Cong Y contributed to validation, visualization; Zheng R, Li M, Xiu Z and Hu PF contributed to data curation; Li M, Xiu Z and Wu GH contributed to investigation; Lianhua CG and Wan Q contributed to conceptualization and methodology as co-corresponding authors; Wan Q contributed to designing the research, project administration, writing-review and editing; all of the authors read and approved the final version of the manuscript to be published.
AI contribution statement: No AI tools were used to create the content of this manuscript.
Supported by The Youth Research Start-up Fund of the Affiliated Hospital of Inner Mongolia University for Nationalities, No. 2020QNJJ02.
Institutional animal care and use committee statement: The requirement for ethics approval was approved by the Animal Ethics Committee of Affiliated Hospital of Inner Mongolia Minzu University (approval No. NM-LL-2026-05-15-01).
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The raw RNA-seq data generated in this study have been deposited in the NCBI Gene Expression Omnibus under accession number GSE347459 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347459) and will be publicly available upon publication. All other data supporting the findings of this study are available within the article and its Supplementary material.
Corresponding author: Quan Wan, PhD, Associate Chief Physician, Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Minzu University, No. 1742 East Section of Huolinghe Street, TongLiao 028000, Inner Mongolia Autonomous Region, China. wanquan120@126.com
Received: June 9, 2026
Revised: August 13, 2026
Accepted: November 2, 2026
Published online: November 26, 2026
Processing time: 163 Days and 1.2 Hours

Abstract
BACKGROUND

Chronic heart failure (CHF) is a major global public health burden. Mongolian Medicine Xin-II has shown promising clinical efficacy in the management of cardiovascular diseases, including coronary heart disease and arrhythmias. However, its underlying molecular mechanisms remain poorly understood.

AIM

To evaluate the therapeutic effects of Xin-II on CHF and investigate the potential molecular pathways underlying these effects using an integrated approach combining network pharmacology and transcriptomic sequencing.

METHODS

A rat model of CHF was established to assess the therapeutic efficacy of Xin-II. Network pharmacology was used to screen the active components of Xin-II and predict its potential therapeutic targets and key signaling pathways implicated in CHF. Transcriptomic sequencing (RNA-seq) was performed to characterize drug-induced changes in gene expression and further verify the regulatory patterns of candidate signaling pathways identified by network pharmacology.

RESULTS

Xin-II improved cardiac function and mitigated myocardial pathological lesions in rats with CHF. Transcriptomic analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment identified the peroxisome proliferator-activated receptor (PPAR) signaling pathway as the most significantly enriched pathway, suggesting its potential involvement in the therapeutic effects of Xin-II against CHF. Mechanistically, Xin-II modulated the expression of key genes and proteins associated with the PPAR/hypoxia-inducible factor-1 alpha signaling cascade. These findings suggest that Xin-II attenuates CHF through multitarget regulation, with the PPAR/hypoxia-inducible factor-1 alpha axis potentially highlighting an important mechanistic pathway.

CONCLUSION

This study found that XinII ameliorates CHF through multi-target molecular mechanisms, thereby providing insights into the therapeutic effects of Xin-II and supporting its further investigation as a treatment for CHF. Further, these findings establish a valuable paradigm to advance the modernization and broader application of traditional Mongolian medicine.

Key Words: Chronic heart failure; Xin-II; Mongolian medicine; Peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 alpha signaling pathway; Mechanism

Core Tip: This study integrates network pharmacology and RNA-seq to reveal that Mongolian Medicine Xin-II alleviates chronic heart failure by modulating the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 signaling pathway, improving cardiac function and myocardial pathology.



INTRODUCTION

Chronic heart failure (CHF) is a major global public health concern within cardiovascular medicine. Its prevalence continues to increase as the population ages, and the 5-year mortality rate remains close to 50%[1]. Although modern therapies, including neurohormonal antagonists, device-based interventions, and cardiac rehabilitation, have substantially improved CHF management, long-term prognosis remains poor. This is particularly true for patients with heart failure with preserved ejection fraction (EF), for whom effective treatment options remain limited[2]. In this context, multi-target therapeutic strategies derived from traditional medical systems have attracted increasing academic interest.

Mongolian medicine uses a holistic approach that focuses on regulating bodily functions and improving organ function. In addition to yielding favorable short-term clinical outcomes, it has a relatively low long-term recurrence rate and minimal reported side effects, thereby addressing both the symptoms and the underlying cause of diseases. This unique approach offers new theoretical insights and therapeutic options for coronary heart disease, and it therefore holds significant clinical and research value[3-5]. Furthermore, as an important component of traditional Chinese medicine, Mongolian medicine has accumulated extensive clinical experience in the prevention and treatment of various cardiovascular diseases. Mongolian Medicine Xin-II is a commonly used traditional Mongolian herbal formulation composed of 17 medicinal ingredients: (1) Nutmeg; (2) Gypsum fibrosum; (3) Rabbit heart; (4) Agarwood; (5) Borneol; (6) Amomum fruit; (7) Ophiopogon root; (8) Asafoetida; (9) Artificial calculus bovis; (10) Choerospondias fruit; (11) Sandalwood; (12) Lightyellow sophora root; (13) Safflower; (14) Aucklandia root; (15) Frankincense; (16) Clove; and (17) Purple sal ammoniac. This formulation is traditionally used to “separate turbidity from clarity”, “tonify the heart”, and promote blood circulation, thereby demonstrating potential in the management of cardiovascular conditions such as coronary heart disease, chest tightness, and shortness of breath[6,7]. In addition, it is thought to regulate imbalances in qi and blood, enhance blood supply to the heart and brain, and strengthen myocardial contractility. Clinically, it has been applied to manage cardiomyopathy, hyperthyroidism, insufficient cardiac and cerebral blood perfusion, and autonomic nervous system dysfunction, with particularly notable efficacy in coronary heart disease and various types of arrhythmias[8]. Previous reports suggest that Xin-II may have therapeutic effects in dilated cardiomyopathy and stable angina[9,10]. However, because Xin-II is a multi-component and multi-target formula, its regulatory mechanisms remain unclear and require systematic investigation.

The rapid development of systems biology has provided powerful tools for elucidating the mechanisms of Mongolian herbal formulas. Network pharmacology, which is based on drug-target-disease interaction networks, can be used to predict potential active components, therapeutic targets, and related signaling pathways, thereby helping to explain the synergistic actions of compound formulas from a holistic perspective[11]. Transcriptomics (RNA-seq), by contrast, provides an unbiased genome-wide assessment of differentially expressed genes before and after drug intervention, reflecting molecular events that occur in response to treatment under pathological conditions[12]. In cardiovascular research, the integration of network pharmacology and transcriptomics can support both theoretical prediction and experimental validation. These complementary approaches may therefore help clarify the molecular mechanisms through which Xin-II acts in CHF.

Therefore, this study established a rat model of CHF to evaluate the therapeutic effects of Xin-II and investigate its possible molecular mechanisms. Network pharmacology was used to screen the active components of Xin-II and predict potential targets and pathways involved in CHF regulation. Subsequently, transcriptomic sequencing was performed to analyze changes in gene expression after Xin-II intervention, with particular attention to pathways regulated by the network pharmacology analysis. Together, these approaches were used to explore the anti-CHF effects of Xin-II and provide a scientific basis for its potential clinical application.

MATERIALS AND METHODS
Experimental animals

Male specific pathogen-free Sprague-Dawley rats with a body weight of 200 ± 20 g and uniform age, as well as healthy coat condition, were obtained from Beijing Sbeifu Biotechnology Co., Ltd. [Animal Production License: SCXK (Jing) 2024-0001]. Prior to experimentation, all animals were acclimated for 7 days in the Experimental Animal Center of Affiliated Hospital of Inner Mongolia Minzu University. The rats were housed under controlled environmental conditions: Constant temperature (23 °C ± 1 °C), relative humidity (40% ± 5%), and a 12 hours light/dark cycle, with regular sanitation maintained throughout the rearing period. All animal procedures complied with the ethical guidelines for laboratory animal use and were approved by the Animal Ethics Committee of Affiliated Hospital of Inner Mongolia Minzu University (approval No. NM-LL-2026-05-15-01). All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the ARRIVE 2.0 guidelines.

Experimental reagents

Mongolian Medicine Xin-II (M20210127000) was prepared following the institution’s approved standard operating procedures and quality control specifications for hospital preparations. The preparation process, including raw material sourcing, extraction, and formulation, follows a standardized protocol. Tween 80 (Tianjin Zhiyuan Chemical Reagents Co., Ltd.), Sodium pentobarbital [Merk (China) official website DS179], Isoflurane (Shenzhen Ruowode Life Science Technology Co., Ltd. R510-22), Lactate Dehydrogenase Assay Kit (Nanjing Jiancheng Bioengineering Institute, A020-2-2), Cardiac Troponin I (Nanjing Jiancheng Bioengineering Institute, H149-2-2), Cardiac Troponin T (Nanjing Jiancheng Bioengineering Institute, H149-2-2), N-terminal pro-brain natriuretic peptide (Nanjing Jiancheng Bioengineering Institute, H334-1-2), Creatine Kinase Assay Kit (Nanjing Jiancheng Bioengineering Institute, A032-1-1), ATP Assay Kit (Wuhan Saipei Biotechnology Co., Ltd.; SP 13572), 4% paraformaldehyde fixative (Guangzhou Chemical Reagent Factory, China), hematoxylin-eosin (Beijing Solabio Biotechnology Co., Ltd.), Masson’s trichrome staining kit (Beijing Solabio Biotechnology Co., Ltd.), G1006; Reagents for CTAB method [Sangon Biotech (Shanghai) Co., Ltd., A600108-0500]; Reagents for CTAB method (Hangzhou Bioer Technology Co., Ltd., BSC55M1); DNA removal (New England Biolabs, M0303S); DNA removal (New England Biolabs, B0303S); Reagents for phenol and guanidine isothiocyanate method (Vazyme Biotech Co., Ltd., R411-02); Universal extraction reagent (Thermo Fisher, AM9920); RNA concentration assay (Vazyme Biotech Co., Ltd., EQ212-02); mRNA capture kit (Vazyme Biotech Co., Ltd., N403-C4); Library preparation reagents (Vazyme Biotech Co., Ltd., NR616-02); DNA purification and sorting magnetic beads (Vazyme Biotech Co., Ltd., N411-03); DNA elution (Thermo Fisher, AM9930); DNA concentration assay (Vazyme Biotech Co., Ltd., EQ121-02), HIF-1α (Cell Signaling Technology, #14179), PPAR Gamma (Proteintech, 16643-1-AP), RISP (Proteintech, 18443-1-AP), STAT3 (Affinity, #AF6294), Phospho-Stat3 (Tyr705) (Cell Signaling Technology, #9145), Phospho-Stat3 (Ser727) (Cell Signaling Technology, #9134), HIF-1β (Cell Signaling Technology, #5537), GAPDH (Proteintech, 10494-1-AP); and Doxorubicin (MCE, HY-15142).

Establishment of a rat model of CHF and grouped drug administration

After one week of acclimatization, the rats were randomly divided into experimental groups (n = 15) using a computer-generated random number sequence via the GraphPad QuickCalcs online randomizer. With the exception of the control group, rats in each group received intraperitoneal injections of doxorubicin at a dose of 2 mg/kg twice weekly for approximately 6 weeks, during which they were closely monitored. Rats in the model groups gradually exhibited signs such as reduced activity, ruffled and dull fur, and rapid breathing. Some rats may develop ascites, pleural effusion, or scrotal edema. After successful modeling, the rats were grouped and administered oral doses as follows: (1) Control group: An equal volume of saline; (2) Model group: An equal volume of saline; (3) Positive group (Sacubitril Valsartan Sodium Tablets group): 18 mg/kg; (4) Xin-II low-dose group: 0.405 g/kg; (5) Xin-II medium-dose group: 0.81 g/kg; and (6) Xin-II high-dose group: 1.62 g/kg.

Drug administration was continued for 4 weeks, and changes in body weight were recorded throughout the observation period. The exclusion criteria were prespecified before the start of the experiment and included: (1) Death following intraperitoneal injection of doxorubicin; (2) Severe deterioration in general condition within 3 days after model establishment due to infection or severe anorexia; and (3) Absence of heart failure confirmed by echocardiography. All exclusion decisions were made by a researcher who was unaware of group assignments. The investigator performing the exclusions was blinded to group allocation. Histological quantification was also performed by an investigator blinded to group allocation according to prespecified criteria established before data collection. Group codes were not unblinded until all measurements had been completed and recorded.

Ultrasound assessment of cardiac function in rats

To establish a model of CHF, we selected left ventricular EF (LVEF) and left ventricular internal diastolic dimension (LVIDd) as evaluation criteria. The quantitative criteria for successful model establishment were predefined as: A LVEF < 50%, accompanied by an enlarged LVIDd compared to the control group. Animals meeting this hemodynamic cutoff were included in subsequent randomization and drug intervention.

Four hours after gavage and following the final drug administration, cardiac function in rats was assessed using an ultra-high-resolution small-animal ultrasound imaging system. The hair on the rats’ chests was shaved in advance, and after induction of anesthesia with inhaled isoflurane, the rats were secured in a supine position on the operating table. A small amount of coupling agent was applied to the left chest. Using the small-animal ultrasound imaging system, the following parameters were measured: (1) Left ventricular end-diastolic dimension; (2) EF; (3) Left ventricular internal dimension in systole; (4) LVIDd; and (5) Fractional shortening (FS). Data for each parameter were collected over three consecutive cardiac cycles, measured three times, and averaged.

Enzyme profile analysis of cardiac tissue

Accurately weigh 100 mg of cardiac tissue, add 1 mL of lysis buffer, and lyse on ice for 30 minutes. Grind the sample in a glass mortar, then collect the supernatant. Centrifuge at 4 °C at 12000 g for 30 minutes, then collect the supernatant. After performing a BCA protein assay, follow the instructions of the respective ELISA kits for creatine kinase (CK), brain natriuretic peptide (BNP), cTnI, and cTnT, and detect at a wavelength of 450 nm.

Histopathological examination of myocardial tissue

Four to five rats were randomly selected from each group 4 weeks after drug administration. After lethal anesthesia via intraperitoneal injection of sodium pentobarbital, the thoracic cavity was rapidly opened, and the heart was quickly excised. Residual blood was washed away in pre-chilled saline, then perfused the heart with 4% paraformaldehyde to fill the chambers. The hearts were placed in a 4% paraformaldehyde solution for 24 hours of fixation. Following fixation, the heart tip was removed, processed using a Thermo tissue dehydrator and embedding system, and embedded in paraffin. These paraffin-embedded sections were stained with hematoxylin and eosin (HE) and Masson’s stain to observe pathological changes in the myocardial tissue.

Network pharmacology prediction mechanism

The BATMAN-TCM database was utilized, which is a comprehensive database exploring known and predicted interactions between Traditional Chinese medicine compounds and target proteins[13]. This study utilized the BATMAN-TCM database to collect known targets for each small-molecule component of Xin-II. For components without known targets, only candidate target proteins with a Score cutoff ≥ 0.86 and a Druggable Score ≥ 0.1 were listed. To investigate the mechanism by which Xin-II treats CHF, this study used the keyword “heart failure” to collect relevant pathogenic genes associated with CHF from the GeneCards and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Furthermore, Jvenn was used to identify the overlapping targets of Xin-II and CHF, thereby screening candidate therapeutic targets potentially involved in the effects of Xin-II against CHF[14].

In living organisms, genes typically act in concert to produce specific biological effects. Prior to constructing the ingredient-disease-target regulatory network, this study utilized the STRING database to construct a protein-protein interaction network. Subsequently, Cytoscape v3.9.0 was used to construct a regulatory network diagram illustrating the interaction between Xin-II and CHF. Five topological analysis methods implemented in the cytoHubba plugin were then applied to identify active components and hub genes[15]. These five analysis methods are: (1) Degree; (2) Edge percolated component; (3) Maximum neighborhood component; (4) Maximal clique centrality; and (5) Closeness.

To investigate the biological processes and related pathways involving key genes, this study utilized the Metascape database and performed functional enrichment analyses using Gene Ontology Biological Processes, KEGG Pathways, and WikiPathways.

To further evaluate the affinity between small molecules and key proteins as well as the stability of the complexes, this study performed molecular docking using CB-Dock2[16] to assess the affinity between small molecules and key proteins. Next, two representative small-molecule-protein complexes were selected for molecular dynamics simulations to assess the stability of the complexes. The main steps were as follows: (1) The AMBER14 force field was selected to optimize the energy of the protein-ligand system. A periodic boundary simulation cell (10 Å extension) was constructed, filled with TIP3P water molecules (density 0.997 g·L), and 0.9% NaCl was added to simulate the physiological ionic environment; (2) Simulation duration: 25000 ps (25 ns), temperature: 310 K (NVT ensemble, Langevin temperature control) to simulate physiological conditions, pH: 7.4 (physiological conditions), initial structure optimized using the default gradient descent method (500 steps); and (3) Key output metrics: Root Mean Square Deviation to assess overall conformational stability, Root Mean Square Fluctuation to analyze local dynamic fluctuations of active site residues, Radius of Gyration measures the compactness of the protein, binding energy evaluates the energy released during ligand-protein binding, and the free energy landscape (also known as the free energy surface) studies processes such as protein folding and molecular motion, helping us understand the stability and kinetic behavior of molecules under different states.

Transcriptomics

RNA-seq was conducted using six biological replicates from each of the Control, Model, and Xin-II treatment groups, resulting in a total of 18 samples for sequencing. For conventional plant samples, the extraction is carried out by combining the CTAB method and PBIOZOL reagent. For conventional animal samples, the extraction is performed using the phenol and guanidine isothiocyanate method. After the successful extraction, the obtained RNA is dissolved in DEPC water. Subsequently, a Qubit fluorometer is used to accurately quantify the RNA. Meanwhile, the RNA integrity number (RQN value) is detected by a Qsep400 high-throughput biofragment analyzer to ensure that the sample quality meets the library construction standards.

By utilizing the structural characteristic that most eukaryotic mRNAs carry a polyA tail, mRNAs with polyA tails were enriched by Oligo(dT) magnetic beads. The purified mRNAs were cleaved into small fragments with fragmentation buffer at a suitable temperature. First-strand cDNAs were produced by reverse transcription using a random hexamer primer. Second-strand cDNAs are synthesized (strand-specific library: The dUTPs were used instead of dTTPs in the second-strand synthesis to incorporate dUTPs in the second-strand cDNAs, while the high-fidelity DNA polymerase used in this method could not amplify uracil-containing DNA templates, thus realizing the strand-specificity), while simultaneously performing end repair and dA-Tailing. Sequencing adapter ligation was performed, followed by DNA magnetic bead purification and fragment selection after ligation was completed to yield a library with 250-350 bp insert fragments. The ligated products were amplified by PCR and purified again using DNA magnetic beads, where the products were solubilized with nuclease-free water. After the initial library was constructed, a Qubit fluorescence quantifier was used for concentration detection, followed by a Qsep400 high-throughput biofragment analyzer for fragment size detection. The double-stranded DNA library obtained by PCR was subjected to single-stranded cyclization to obtain a single-stranded circular DNA library. The final library was amplified with phi29 before uploading to make DNA nanoballs (DNB) with more than 300 copies of a molecule, and the DNBs were loaded into the sequencing chip and sequenced on the MGI sequencing platform.

The Benjamini-Hochberg procedure was applied to adjust P values for multiple testing and control the false discovery rate. Genes with an adjusted P value (padj) < 0.05 and an absolute log2 fold change (|log2FC|) ≥ 1 were considered differentially expressed. The raw and processed RNA-seq data have been deposited in the NCBI Gene Expression Omnibus under accession number GSE347459.

Western blot analysis of proteins associated with the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 alpha signaling pathway

Prepare SDS-PAGE gels, prepare rapid electrophoresis buffer and transfer buffer, and perform electrophoresis at a constant voltage of 120 V for 1 hour with 30 μg of protein per well, followed by membrane transfer at a constant current of 400 mA for 60 minutes. After electrophoresis, transfer the PVDF membrane to 5% skim milk and incubate at room temperature for 1 hour; after blocking, transfer the PVDF membrane to the corresponding primary antibody solution and incubate overnight at 4 °C (1:1000); The next day, remove the PVDF membrane and place it in 1 × TBST. Wash it five times on a horizontal shaker for 5 minutes each. After washing, incubate the PVDF membrane in the secondary antibody solution (1:5000) at room temperature for 1 hour; wash the PVDF membrane five times in 1 × TBST on a horizontal shaker for 5 minutes each. Expose and acquire protein images in the darkroom using the Odyssey CLX gel imaging system; GAPDH was used as the protein reference in this experiment. The grayscale values of the target protein bands were analyzed using the ImageJ image analysis system, and the relative expression levels of the target proteins were obtained after normalization against the internal control.

RNA extraction, reverse transcription, and real-time quantitative PCR

Nuclease-free pipette tips and centrifuge tubes were used throughout this experiment. The specific procedure for RNA extraction is as follows. After processing, the supernatant was removed from the heart tissue samples in each group. The samples were washed three times with 1 × PBS, then 1 mL of TriZol was added and the samples were lysed on ice for 15 minutes. The lysate was transferred to 1.5 mL Eppendorf tubes. Add 200 μL of chloroform to the EP tube, vortex for 30 seconds, let stand at room temperature for 5 minutes, then centrifuge at 12000 g for 15 minutes at 4 °C; Transfer 500 μL of the aqueous phase to an RNase-free centrifuge tube, add an equal volume of isopropanol, gently invert to mix, and incubate at room temperature for 5 minutes. Centrifuge at 12000 ×g at 4 °C for 15 minutes. Discard the supernatant, add 75% ethanol, and centrifuge at 8000 ×g at 4 °C. Discard the supernatant, let the pellet air-dry, add 30 μL of enzyme-free sterile water to dissolve the RNA, and determine the concentration.

Take 1000 ng of the RNA solution for reverse transcription to obtain cDNA. The reaction system required for reverse transcription is shown in Table 1. Place 20 μL of the prepared reverse transcription reaction mixture into a PCR instrument for reaction: (1) 5 minutes at 25 °C; (2) 15 minutes at 50 °C; (3) 2 minutes at 85 °C; and (4) Then store at 4 °C.

Table 1 Reverse transcription system.
Reagents
Volume
RNase-free ddH2O20 μL
2 × RT Mix10 μL
HiScript II Enzyme Mix2 μL
Oligo(dT)1 μL
Random hexamers1 μL
Total RNA1000 ng
Total volume20 μL

Design the primers required for the real-time quantitative PCR (qRT-PCR) experiment; the primers used in this experiment were synthesized by Shanghai Sangon Biotech. The primer sequences are shown in Table 2: Dilute the cDNA solution obtained above 5-fold to prepare the qRT-PCR reaction mixture. The qRT-PCR reaction system is shown in Table 3. Place 10 μL of the prepared qRT-PCR reaction mixture into the PCR instrument for reaction: Pre-denature at 95 °C for 30 seconds, followed by 40 cycles of the amplification phase (5 seconds at 95 °C and 30 seconds at 60 °C), then store at 4 °C. After obtaining the CT values for the genes, select β-actin as the internal reference gene and use the 2-ΔΔCT formula to calculate the relative mRNA expression levels of the target genes.

Table 2 The qPCR reaction system.
Reagents
Volume
TB Green Premix Ex Taq5 μL
Forward Primer0.5 μL
Reverse Primer0.5 μL
cDNA1 μL
RNase-free ddH2O3 μL
Total volume10 μL
Table 3 Internal primer sequences for target genes (5’-3’).
Primer name
5’-3’ primer sequence
PCK1 forwardTGTTGGCTGGCTCTCACTGAC
PCK1 reverseGTCTCTCTGCTCTTGGGTAATGATG
GAPDH forwardTTCAACGGCACAGTCAAG
GAPDH reverseTACTCAGCACCAGCATCA
Statistical analysis

All experimental data in this study are presented as mean ± SD. For comparisons between two groups, an independent samples t-test was used to analyze differences, while for comparisons among multiple groups, a one-way analysis of variance was performed after verifying the homogeneity of variances. A one-way analysis of variance was performed, followed by Tukey’s HSD post hoc test for multiple comparisons, assuming homogeneity of variances. Statistical analysis of the experimental data and the creation of visual charts were performed using GraphPad Prism software (version 8.0), and the criterion for statistical significance was set at P < 0.05.

RESULTS
Efficacy of Xin-II in treating CHF

The experimental protocol is summarized in Figure 1A. During the experiment, rats in the control group had bright, glossy coats, remained highly responsive, and maintained normal food and water intake; no deaths occurred in this group. By contrast, rats in other groups appeared lethargic, had dull and sparse coats, cold skin, reduced activity, low food and water intake, and, in some cases, loose or watery stools. Rats in the drug-treated groups showed modest improvements in general condition compared with the model group, although their coats remained less glossy than those of the control group and their food and water intake remained slightly reduced. In the body-weight curve (Figure 1B), body weight in the model group was significantly lower than that in the control group throughout the experiment (P < 0.05). No significant differences in body weight were observed among the other groups. The doxorubicin-induced CHF model was associated with mortality during model establishment. Mortality was relatively high in the model group, approaching 45%, whereas drug intervention reduced average mortality to approximately 20% (Figure 1C).

Figure 1
Figure 1 Efficacy of Xin-II in treating chronic heart failure. A: Flowchart of the animal experiment; B: Graph showing body weight statistics for each group; C: Mortality statistics for each group; D: Cardiac function testing in animals (n = 3); E: Statistical results of echocardiography (n = 3). Data are presented as mean ± SEM. Statistical significance was determined by one-way analysis of variance followed by Tukey’s multiple comparisons test. aP < 0.05 (control vs model group); bP < 0.05 (model vs Xin-II group). NS: Not significant; CK: Creatine kinase; BNP: Brain natriuretic peptide; EF: Ejection fraction; FS: Fractional shortening; LVIDd: Left ventricular internal diastolic dimension; LVIDs: Left ventricular internal dimension in systole.

As shown in Figure 1D, the levels of CK, BNP, cTnT, and cTnI in the myocardial tissue of rats with CHF were significantly increased compared with those in the control group (P < 0.05). These findings are consistent with those observed in clinical CHF, indicating that the rat model exhibited good reproducibility and stability. Following drug intervention, the levels of CK, BNP, cTnT, and cTnI in all drug-treated groups decreased significantly compared with those in the model group (P < 0.05). Also, the reversal effects observed after treatment were significantly different from those in the model group. Compared with the control group, myocardial adenosine triphosphate (ATP) levels were significantly reduced in the model group (P < 0.05), indicating impaired mitochondrial energy metabolism in CHF. Compared with the model group, Xin-II treatment significantly restored myocardial ATP levels (P < 0.05), indicating that Xin-II may improve myocardial energy metabolism (Supplementary Figure 1).

Six weeks after model establishment and before drug intervention, all enrolled animals underwent baseline echocardiographic evaluation. The mean LVEF in the model group was reduced to 44.90% ± 3.43%, meeting the predefined criteria for model success. Baseline echocardiographic parameters were comparable between the model group and Xin-II treatment groups before drug administration. No significant differences were found in LVEF (46.56% ± 1.43% vs 45.76% ± 1.12%, P = 0.72), LVIDd (0.85 ± 0.03 cm vs 0.83 ± 0.01 cm, P = 0.28), or FS (P = 0.27) (Table 4). These findings suggest that the two groups had comparable cardiac function at the start of the treatment period.

Table 4 Statistical table of baseline ultrasound parameters before drug administration, mean ± SD.
Group
LVEF
LVFS
LVIDd
LVIDs
Model group46.56 ± 1.4325.54 ± 0.270.85 ± 0.030.40 ± 0.09
Drug group45.76 ± 1.1224.66 ± 1.460.83 ± 0.010.47 ± 0.01

Four weeks after drug administration, rats were anesthetized with inhaled isoflurane, secured in the supine position, and examined by cardiac ultrasound. In the control group, ventricular wall motion was uniform and the atrial-to-ventricular ratio was normal. In the model group, ventricular wall motion was markedly reduced, accompanied by left ventricular dilation and pathological hypertrophy. LVIDd, LVEF, and FS were measured in all groups. CHF model rats exhibited impaired cardiac function, left ventricular dilation, abnormal contractility, and reduced stroke volume compared with the control group (P < 0.05; Figure 1E). Drug treatment delayed the progression of cardiac dilation and dysfunction, with the high-dose Xin-II group showing the strongest effect. These findings suggest that Xin-II, like the positive control drug, reduced left ventricular dilation, improved myocardial contractility and compliance, and protected damaged myocardium.

Histopathological examination of myocardial tissue in rats with CHF after Xin-II treatment

Rat heart tissue was fixed with paraformaldehyde, and a tissue section slightly larger than the CHF-affected ventricular region was excised and dehydrated using an automatic tissue dehydrator. After paraffin embedding, serial sections of 4 μm thickness were prepared. The sections were stained according to the HE staining protocol and immediately mounted with neutral resin. In the normal group, myocardial cells were regularly and neatly arranged, with intact structures, uniformly distributed nuclei, and consistent intercellular spaces. Myocardial fibers were orderly arranged and uniformly stained. No obvious cellular edema, necrosis, or myofibrillar fragmentation was observed, although minimal inflammatory cell infiltration and fibrotic hyperplasia associated with control were present (Figure 2A). Compared with the control group, the model group showed obvious pathological changes on HE staining, including disorganized myocardial fibers and inflammatory cell infiltration. After treatment with different doses of Xin-II, myocardial lesions showed a trend toward improvement.

Figure 2
Figure 2 Histopathological images of heart tissue. A: Hematoxylin and eosin staining; B: Masson staining.

During CHF progression, the heart develops pathological changes such as fibrotic repair, compensatory hypertrophy, and myocardial remodeling. Masson staining can be used to visualize collagen fiber distribution within myocardial tissue and around blood vessels. In the control group, myocardial fibers were neatly and orderly arranged, with predominantly red-stained cardiomyocytes, uniform cytoplasmic staining, and clear boundaries. A small number of blue collagen fibers were scattered in the intercellular spaces, and no obvious left ventricular fibrosis was observed. Compared with the normal group, myocardial tissue in the model group showed substantial damage, including fibrosis and tissue remodeling, with increased collagen deposition. Compared with the model group, all drug-treated groups showed reduced myocardial fibrosis, decreased blue collagen fiber area, and more orderly myocardial bundle arrangement (Figure 2B).

Regulatory network analysis of Xin-II

Database screening identified 221 potential active components in Xin-II and 1147 associated targets. In addition, 1036 genes associated with heart failure were identified, with 72 overlapping targets (Figure 3A). Among the medicinal components of Xin-II, safflower contributed the largest number of components (n = 51), followed by Choerospondias Fruit (n = 50). The component-disease-target regulatory network contained 307 nodes and 1764 edges (Figure 3B). Degree analysis showed that safflower, Choerospondias Fruit, Clove, and Lightyellow Sophora Root were the top four medicinal components by degree. Among the predicted active compounds, quercetin, wogonin, and kaempferol ranked highest, with degree values of 35, 16, and 15, respectively. Among the core targets, tumor necrosis factor, interleukin (IL)-6, IL-1β, prostaglandin endoperoxide synthase 2, and peroxisome proliferator-activated receptor γ (PPARγ) ranked in the top five by degree value.

Figure 3
Figure 3 Network pharmacology of Xin-II in the treatment of chronic heart failure. A: Identification of overlapping targets between Xin-II and heart failure; B: Regulatory network diagram of Xin-II-heart failure-interacting targets; C: Screening of key targets using five topological parameters; D: Enrichment analysis of biological processes and pathways; E: Identification of core targets for Xin-II in the treatment of chronic heart failure; F: Molecular docking results. HFrEF: Heart failure with reduced ejection fraction.

To further identify key targets, five topological parameters were analyzed, and the top 20 targets for each parameter were compared. The screening results for maximal neighborhood component (maximum neighborhood component), degree, and closeness were broadly consistent. Based on this analysis, 17 targets, including tumor necrosis factor, IL-6, and PPARγ, were identified as potential key targets through which Xin-II may affect heart failure (Figure 3C).

Gene Ontology enrichment analysis using R identified 2513 enriched terms, including 2356 biological process terms, 113 molecular function terms, and 44 cellular component terms (Figure 3D). The main biological process terms were related to the regulation of smooth muscle cell proliferation and the positive regulation of oxidoreductase activity. The main molecular function terms included receptor ligand activity, cytokine activity, and cytokine receptor binding. The main cellular component terms involved the endoplasmic reticulum lumen, blood microparticles, and the RNA polymerase II transcription regulator complex. Metascape analysis identified 157 enriched pathways. Among the eight representative pathways, vitamin B12 metabolism, adipogenesis, the hypoxia-inducible factor-1 (HIF-1) signaling pathway, and the galanin receptor pathway may be particularly relevant. Across these eight pathways, the five most frequently occurring genes were IL-6 (7), STAT3 (7), EDN1 (6), IFNG (5), and INS (5).

Heart failure is a complex clinical syndrome caused by structural or functional cardiac abnormalities that impair ventricular filling or ejection. Heart failure is generally defined by a LVEF of ≤ 40%, whereas an LVEF of 41%-49% is classified as mildly reduced CHF. Using GeneCards, this study identified 60 representative CHF-related genes, among which ADIPOQ, EDN1, and IL-6 were identified as core targets (Figure 3E). In CHF, EDN1 and IL-6 may contribute to disease progression, whereas elevated ADIPOQ may reflect a compensatory response or disease severity. IL-6-related and EDN1-related therapeutic strategies have been proposed as potential approaches[17,18], while ADIPOQ is often discussed as a biomarker of metabolic status[19]. These findings suggest that Xin-II may exert some of its therapeutic effects in CHF through these three genes.

Because IL-6 had the highest score and appeared frequently in the enrichment analysis, it was selected for molecular docking with the three highest-ranked compounds: (1) Quercetin; (2) Wogonin; and (3) Kaempferol. All three small molecules showed favorable predicted affinity for IL-6, with binding energies below -5 kcal/mol (Figure 3F). In the target-small molecule complexes, the binding coordinates were within the range of -5, -30, and 7. The small molecules were predicted to bind within IL-6, with interactions mainly involving hydrogen bonds, followed by π-π stacking and π-alkyl interactions.

We also performed molecular docking to assess the interactions of the top three compounds, quercetin, wogonin, and kaempferol, with PPARγ and HIF-1α. All three compounds exhibited favorable predicted binding affinity for both PPARγ and HIF-1α, with binding energies below -6 kcal/mol (Supplementary Figure 2). The docking results show that these compounds bind to the interior of PPARγ and HIF-1α, with hydrogen bonding facilitating the predicted interactions. These findings support the potential of quercetin, wogonin, and kaempferol to interact with PPAR and HIF-1α. However, the pathway annotations and docking findings are derived from exploratory bioinformatics analyses and should therefore be considered hypothesis-generating results that require experimental validation.

Analysis of transcriptomic results

Transcriptomic data provide sensitive genome-wide detection of gene expression. FPKM values for protein-coding genes typically span several orders of magnitude, ranging from 10-2 to 104. Box plots can be used to assess the distribution and dispersion of gene expression levels within individual samples and to compare overall expression patterns across groups. The FPKM distribution box plots are presented for each sample (Figure 4A and B).

Figure 4
Figure 4 Transcriptomics. A: Overall distribution of gene expression levels across samples; B: Density plot of expression levels; C: Principal component analysis plot of samples across groups (two-dimensional); D: Principal component analysis plot of samples across groups (three-dimensional); E: Sample correlation plot; F: Statistical plot of differentially expressed genes across groups; G: Volcano plot of differential genes; H: K-means clustering chart; I: Venn diagram of differentially expressed genes across groups.

Principal component analysis (PCA) is a statistical method for analyzing multidimensional data in unsupervised pattern recognition. By applying orthogonal transformation, PCA converts potentially correlated variables into a set of linearly uncorrelated variables, known as principal components. This analytical method is often used to reveal the internal relationships among multiple variables using a small number of principal components. Specifically, these principal components retain most of the information contained in the original variables while remaining uncorrelated with one another. Mathematically, this is typically achieved through linear combinations of the original variables to form new composite variables. In this study, PCA analysis was performed on the expression profiles of the control group, model group, and Xin-II group to evaluate the degree of variability in the transcriptome within and between groups. As shown in Figure 4C and D, the distribution trend of transcriptomic expression levels demonstrated clear clustering within groups and separation between groups, indicating good reproducibility among samples within each group as well as significant differences between groups. Partial overlap between groups was also noted, suggesting the presence of shared transcriptomic characteristics. As shown in Figure 4E, the heatmap of inter-sample correlation coefficients indicates high overall consistency among the samples, with correlation coefficients ranging from 0.88 to 0.99. Samples within each group showed high correlations, indicating good consistency and reproducibility of the transcriptomic data, whilst there was relatively low correlation between groups.

Based on the differential RNA screening criteria, transcriptomic expression levels among the control group, model group, and Xin-II group were compared to identify statistically significant differences between groups. Compared with the control group, the model group showed a total of 4489 differentially expressed genes, including 2135 upregulated genes and 2354 downregulated genes. When comparing the model group with the Xin-II group, a total of 2838 differentially expressed genes were identified, including 1383 upregulated genes and 1455 downregulated genes. In addition, comparison between the control group and the Xin-II group revealed a total of 1595 differentially expressed genes, of which 494 were upregulated genes and 1101 were downregulated genes, as shown in Figure 4F and G.

To systematically analyze the time-dependent molecular responses to Xin-II intervention, unsupervised K-means clustering was performed on the 4489 differentially expressed genes identified in the transcriptomic analysis (Figure 4H). The optimal number of clusters (K) was determined based on a comprehensive evaluation of the rule-of-thumb criteria and silhouette coefficient. The genes were divided into three clusters with distinct expression trends. Cluster 1, containing 3504 genes, exhibited low expression in the control group, increased expression in the model group, and subsequently decreased expression after Xin-II treatment. In contrast, cluster 3, containing 895 genes, showed the opposite pattern, suggesting that these genes may be involved in the response to Xin-II treatment. The expression patterns of the three clusters are shown in Figure 4H. Co-expression analysis was performed across the three datasets, with each group represented by a different color (Figure 4I). The numbers inside the circles indicate the number of genes in each category. A total of 212 genes were shared among the three groups. The control group contained 2041 genes that were unique compared with the model group, while the model group contained 786 genes that were unique compared with the Xin-II group.

Enrichment analysis of differentially expressed genes

KEGG enrichment analysis was performed for the differentially expressed genes in each comparison group. The 50 KEGG pathways with the lowest q-values were selected, and the enriched terms were visualized as a bar chart (Figure 5A). The 20 most significantly enriched pathway entries are presented separately, with a higher rich factor indicating a greater degree of enrichment (Figure 5B). The PPAR signaling pathway was among the prominent enriched pathways and may be closely associated with CHF-related changes in this model. The KEGG enrichment results for each comparison were sorted by q-value, and the union of the 15 pathways with the lowest q-values from each group was displayed (Figure 5C). The top-ranked enriched pathways included diabetic cardiomyopathy, chemical carcinogenesis-reactive oxygen species, and amyotrophic lateral sclerosis, among others. As shown in Figure 5D, the five KEGG pathways with the lowest q-values in the comparison between the model and Xin-II groups were selected for enrichment analysis and plotted using a KEGG enrichment circle plot. The enriched pathways were spread across four KEGG categories: (1) Cellular processes, including focal adhesion, peroxisome, and gap junction; (2) Organismal systems, including thermogenesis, retrograde endocannabinoid signaling, and cardiac muscle contraction; (3) Metabolism, including pyruvate metabolism, valine, leucine and isoleucine degradation, and carbon metabolism; and (4) Human diseases, including Huntington’s disease, Parkinson’s disease, prion disease, chemical carcinogenesis – reactive oxygen species, and diabetic cardiomyopathy.

Figure 5
Figure 5 Enrichment analysis of differentially expressed genes. A: Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment of differentially expressed genes; B: KEGG enrichment scatter plot; C: Multi-group KEGG enrichment scatter plot; D: KEGG enrichment circle plot of differentially expressed genes between the model vs Xin-II group.
Validation of proteins related to the PPAR/HIF-1α signaling pathway and candidate genes

The qRT-PCR was used to validate the expression levels of selected differentially expressed genes. The qPCR results for the candidate genes are presented in Figure 6A. Compared with the control group, phosphoenolpyruvate carboxykinase 1 (PCK1) expression was significantly upregulated in the model group (P < 0.05). Compared with the model group, PCK1 expression was significantly downregulated in the Xin-II group (P < 0.05).

Figure 6
Figure 6 Xin-II significantly modulates protein levels in the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 alpha signaling pathway to alleviate chronic heart failure. A: The qPCR results for differentially expressed genes identified by transcriptomics; B-I: Protein expression levels of the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 alpha signaling pathway (assessed by western blot). B-H show bar charts (with GAPDH as the internal control); I shows the protein band patterns for each protein. Quantification of protein expression levels via grayscale analysis. Data are presented as mean ± SEM. Statistical significance was determined by one-way analysis of variance followed by Tukey’s multiple comparisons test. aP < 0.05 (control vs model group); bP < 0.05 (model vs drug-treated group). PCK1: Phosphoenolpyruvate carboxykinase 1; PPAR: Peroxisome proliferator-activated receptor; HIF: Hypoxia-inducible factor; RISP: Rieske iron sulfur protein; STAT3: Signal transducer and activator of transcription 3.

Protein validation for the PPAR/HIF-1α signaling pathway is presented in Figure 6B-I. Compared with the control group, protein levels of PPAR γ, HIF-1α, and HIF-1β were significantly decreased in the model group (P < 0.05), whereas STAT3 and Rieske iron sulfur protein (RISP) protein levels were significantly elevated (P < 0.05). Compared with the model group, the Xin-II group showed an upward trend in the protein levels of PPARγ, HIF-1α, and HIF-1β. However, these changes were not statistically significant (P > 0.05). In contrast, compared with the model group, the Xin-II group showed significantly reduced levels of STAT3 and RISP proteins (P < 0.05).

To further assess STAT3 activation, the phosphorylation levels of p-STAT3 (Tyr705) and p-STAT3 (Ser727) were evaluated relative to total STAT3. The results showed that, compared with the control group, the ratio of p-STAT3 (Tyr705)/total STAT3 was significantly elevated in the model group (P < 0.05), whereas the p-STAT3 (Ser727)/total STAT3 ratio showed no significant change (P > 0.05). These findings suggest that the altered STAT3 activation status in CHF may be associated with phosphorylation at Tyr705 rather than Ser727.

DISCUSSION

The prevalence of heart failure remains high, with ischemic heart disease being a leading cause of heart failure[20]. Current treatments for heart failure include diuretics, renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, soluble guanylate cyclase stimulators, and aldosterone receptor antagonists[21]. These treatments can alleviate clinical symptoms and improve prognosis. However, adverse effects, treatment costs, and incomplete therapeutic responses remain challenges. Therefore, further investigation of the molecular mechanisms underlying heart failure is important to support the development of additional therapeutic strategies.

Xin-II has been reported to enhance myocardial function and regulate the balance of qi and blood, with few adverse reactions, thereby supporting its potential clinical use. Its active components include quercetin, wogonin, and kaempferol[22-24]. These flavonoids have diverse biological activities, including antioxidant, anti-inflammatory, and antitumor effects. In addition, each compound demonstrates unique effects on metabolic regulation and mitochondrial function.

CHF involves complex pathophysiological mechanisms, including mitochondrial dysfunction, excessive reactive oxygen species production, inflammation, autophagy, ferroptosis, and disordered energy metabolism. Interactions among these mechanisms contribute to the complexity of CHF pathogenesis[25]. Comprehensive molecular analyses are therefore needed to understand CHF progression and identify therapeutic targets. Transcriptomic approaches have identified biomarkers associated with CHF progression and may improve mechanistic understanding of the disease[26,27]. By identifying CHF-associated genes through differential transcriptomic analysis, researchers can obtain useful guidance for investigating molecular therapeutic targets and pathological mechanisms.

Network pharmacology relies on database screening and computer simulations, and the reliability of its predictive results is important for guiding subsequent experimental validation. As such, the selection of molecular docking targets should be biologically consistent with the pathways investigated experimentally[28]. The present study did not focus solely on initially identified inflammatory targets such as IL-6, and instead, performed molecular docking between the core active compounds and PPARγ and HIF-1α, which were chosen as key proteins for experimental validation. The three core compounds exhibited strong predicted binding affinity to both PPARγ and HIF-1α, with binding energies below -6.2 kcal/mol, and formed stable hydrogen bonds with key amino acid residues. These findings provide computational support for the potential interactions of the core compounds with PPAR and HIF-1α, laying a solid foundation for further investigation of the PPAR/HIF-1α pathway as a mechanism underlying the effects of Xin-II (Figure 7).

Figure 7
Figure 7 Mechanism diagram. Dotted arrows and question marks indicate predictions or unconfirmed pathways that require causal validation. FAO: Fatty acid oxidation; PPAR: Peroxisome proliferator-activated receptor; HIF: Hypoxia-inducible factor; RISP: Rieske iron sulfur protein; STAT3: Signal transducer and activator of transcription 3; CHF: Chronic heart failure.

An integrated analysis of network pharmacology and transcriptomic data found that the mechanism by which Xin-II inhibits CHF may involve the PPAR/HIF-1α signaling pathway[29]. This pathway was also linked to the key candidate gene PCK1, a downstream effector associated with PPARγ signaling, thereby constructing a coherent framework connecting target prediction with functional validation. In this study, altered expression of PCK1 was observed in myocardial tissue from a doxorubicin-induced rat model of heart failure, further supporting its possible involvement in the response to Xin-II. PCK1 is generally considered a key enzyme in gluconeogenesis and is involved in cellular energy metabolism, including pathways linked to glycolysis and the tricarboxylic acid cycle[30,31]. During heart failure progression, persistent hypoxia and metabolic stress can deplete available substrates and impair ATP production through oxidative phosphorylation. Dysregulated PCK1 expression may therefore contribute to metabolic imbalance in failing rat hearts.

At the molecular validation level, different detection methods were used based on the biological characteristics of each target. First, PCK1 was identified as a differentially expressed gene through unbiased screening of the transcriptome (RNA-seq), and was therefore validated at the mRNA level using RT-qPCR. As a key rate-limiting enzyme in gluconeogenesis, the promoter region of the PCK1 gene is rich in transcription factor-binding elements for FoxO1 and CREB, and changes in its transcriptional levels in response to metabolic stimuli are important for regulating its expression[32]. Therefore, confirming changes in PCK1 mRNA through RT-qPCR was appropriate to meet the technical objectives of transcriptomic validation. Second, PPARγ, HIF-1α, HIF-1β, STAT3, and RISP were evaluated at the protein level. HIF-1α is a typical oxygen-dependent protein, whereby it is rapidly degraded even with high mRNA expression under normoxic conditions. Therefore, protein abundance is especially relevant to its functional activity[33]. Meanwhile, STAT3 is highly dependent on phosphorylation at the Tyr705 and Ser727 sites, which is assessed using specific phosphorylation antibodies[34]. As a nuclear receptor, PPARγ function is regulated by ligand binding and post-translational modifications such as phosphorylation and acetylation, with protein abundance directly reflecting this activity[35]. Finally, RISP is a structural subunit of mitochondrial respiratory chain complex III, and its biological function is dependent on its incorporation into the protein complex[36]. Overall, this detection strategy enabled assessment of both transcript-level changes and protein-level changes relevant to the proposed signaling network.

However, several limitations should be acknowledged. Notably, the multi-target, multi-component nature of Mongolian medicine makes it difficult to attribute its pharmacological effects to a single marker compound. Therefore, comprehensive pharmacokinetic profiling was beyond the scope of the present investigation and should be pursued in future research. In addition, comprehensive chemical fingerprinting and compositional analysis of Xin-II were not carried out. Although Xin-II is a hospital preparation manufactured according to approved standard operating procedures and established quality control parameters, the chemical complexity of the preparation and the lack of fully characterized reference standards for all constituents currently constrain complete chemical profiling. Future studies should employ bioactivity-guided fractionation and advanced analytical techniques, such as UPLC-Q-TOF-MS, to characterize the chemical composition of Xin-II and identify its principal active constituents. Furthermore, although the integrated network pharmacology and transcriptomic analyses identified the PPARγ/HIF-1α pathway as potentially associated with the effects of Xin-II treatment, the causal relationship was not established in this study. Future studies should employ gain-of-function/Loss-of-function strategies, gene knockdown, and pathway-specific inhibitors, to determine whether the cardioprotective effects of Xin-II are causally dependent on this signaling axis. Such studies will move beyond the level of correlational evidence to establish true mechanistic causality. Finally, future studies should focus on three objectives: (1) Identification of the principal active components of Xin-II through bioactivity-guided fractionation; (2) Validation of their molecular effects using purified compounds in controlled cardiomyocyte models; and (3) Validation of the proposed signaling mechanism in an independent animal cohort once the active principles have been characterized.

Although network pharmacology predicted PPARγ and HIF-1α as potential candidate targets, Western blot analysis did not detect statistically significant changes in their protein levels following Xin-II treatment (P > 0.05). In addition, pathway-specific perturbation experiments, such as pharmacological inhibition or gene knockdown/rescue studies, were not performed to establish causal relationships. Therefore, the potential involvement of the PPARγ/HIF-1α axis in the therapeutic effects of Xin-II should be considered hypothesis-generating rather than mechanistically confirmed. These findings provide a rationale for future investigations using conditional gene knockout approaches or pathway-specific pharmacological inhibition to determine the causal role of these pathways in the effects of Xin-II.

The upstream regulatory mechanisms responsible for PCK1 downregulation in CHF remain unclear, and as such, further investigation is needed to determine the signaling pathways involved. Second, tissue-specific experimental approaches targeting PCK1, such as cardiomyocyte-selective knockout models or adeno-associated virus-mediated overexpression, are required to establish causality rather than correlation. Although the relationship between the PPARγ/HIF-1α signaling pathway and PCK1 was not explicitly investigated in the current study, future research should focus on this potential relationship through the use of PPARγ agonists or antagonists, PCK1 knockdown or overexpression in cardiomyocytes, and measurements of downstream metabolic fluxes.

In conclusion, this study provides preliminary evidence that Xin-II exerts cardioprotective effects in a rat model of CHF. Integrative network pharmacology, transcriptomics, and in vivo validation suggest multiple candidate pathways that may contribute to these effects. However, the specific mechanistic pathways (the predicted PPAR/HIF axis) remain unconfirmed. Future studies employing pathway-specific inhibitors or conditional gene knockout models are required to establish causal relationships.

CONCLUSION

This study presents preliminary evidence that Xin-II has a cardioprotective effect in a rat model of CHF. Network pharmacology, transcriptomics, and in vivo validation identified multiple candidate pathways that may contribute to these effects. However, the findings regarding the PPARγ/HIF-1α axis remain unconfirmed, and a causal relationship between this pathway and the effects of Xin-II has not yet been established. Future studies using pathway-specific inhibitors or conditional knockout models are needed to determine a causal relationship between the cardioprotective effects of Xin-II treatment and these candidate signaling pathways.

References
1.  Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3:7-11.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2169]  [Cited by in RCA: 1914]  [Article Influence: 212.7]  [Reference Citation Analysis (3)]
2.  McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 10992]  [Cited by in RCA: 9882]  [Article Influence: 1976.4]  [Reference Citation Analysis (12)]
3.  Wen J, Yao ST. [Clinical Observation of 54 Cases of Coronary Heart Disease Treated with Mongolian Medicine Based on Syndrome Differentiation]. Zhongguo Minzu Yiyao Zazhi. 2016;22:13-14.  [PubMed]  [DOI]  [Full Text]
4.  Arongqiqige, Lu F. [The Academic Thought of the Renowned Elder Mongolian Medicine Practitioner Eerdun and an Observation of the Clinical Efficacy of Mongolian Medicine in the Treatment of Jiruhen Hatlega]. Shijie Zuixin Yixue Xinxi Wenzhai. 2017;17:258-259.  [PubMed]  [DOI]  [Full Text]
5.  Bao SX.   [Clinical Observations on the Treatment of Heart Failure with Preserved Ejection Fraction Using Mongolian Medicine]. Master's Thesis. Inner Mongolia Minzu University, 2024.  [PubMed]  [DOI]  [Full Text]
6.  Zhang QS, Zhao M.   [A Study on the Mechanism of Action of Mongolian Medicine No. II on Cardiac Function in Patients with Dilated Cardiomyopathy]. Affiliated Hospital of Inner Mongolia Minzu University, 2021.  [PubMed]  [DOI]
7.  Ce·Surongzhabu.   Internal Medicine in Mongolian Medicine. Hohhot: Inner Mongolia People’s Publishing House, 2015: 237-245.  [PubMed]  [DOI]
8.  Ao LL.   [Clinical Study of Mengyao Xin-II for the Treatment of Heart Failure with Preserved Ejection Fraction]. Master's Thesis. Inner Mongolia Minzu University, 2020.  [PubMed]  [DOI]  [Full Text]
9.  Aruhan.   [Clinical Observation on the Use of Mengyao Xin-II in Combination with Western Medicine for the Treatment of Stable Angina Pectoris]. Master's Thesis. Inner Mongolia Minzu University, 2025.  [PubMed]  [DOI]  [Full Text]
10.  Sarula.   [A Clinical Study on the Efficacy of Mengyao Xin-II Combined with Western Medication in the Treatment of Dilated Cardiomyopathy]. Master's Thesis. Inner Mongolia Minzu University, 2024.  [PubMed]  [DOI]  [Full Text]
11.  Liu X, Zhan Z, Zhang R, Wang Y, Xu Q. Network pharmacology-based prediction and molecular docking-based strategy to investigate the potential mechanism of Leonurus japonicus Houtt. Against myocardial ischemia reperfusion injury. J Cardiothorac Surg. 2025;20:204.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
12.  Hrdlickova R, Toloue M, Tian B. RNA-Seq methods for transcriptome analysis. Wiley Interdiscip Rev RNA. 2017;8.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 305]  [Cited by in RCA: 455]  [Article Influence: 45.5]  [Reference Citation Analysis (0)]
13.  Kong X, Liu C, Zhang Z, Cheng M, Mei Z, Li X, Liu P, Diao L, Ma Y, Jiang P, Kong X, Nie S, Guo Y, Wang Z, Zhang X, Wang Y, Tang L, Guo S, Liu Z, Li D. BATMAN-TCM 2.0: an enhanced integrative database for known and predicted interactions between traditional Chinese medicine ingredients and target proteins. Nucleic Acids Res. 2024;52:D1110-D1120.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 55]  [Cited by in RCA: 144]  [Article Influence: 72.0]  [Reference Citation Analysis (2)]
14.  Bardou P, Mariette J, Escudié F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15:293.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2062]  [Cited by in RCA: 1805]  [Article Influence: 150.4]  [Reference Citation Analysis (7)]
15.  Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8 Suppl 4:S11.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 4900]  [Cited by in RCA: 4540]  [Article Influence: 378.3]  [Reference Citation Analysis (6)]
16.  Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 2022;50:W159-W164.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1491]  [Cited by in RCA: 1367]  [Article Influence: 341.8]  [Reference Citation Analysis (2)]
17.  Docherty KF, McDowell K, Welsh P, Petrie MC, Anand I, Berg DD, de Boer RA, Køber L, Kosiborod MN, Martinez FA, O'Meara E, Morrow DA, Ponikowski P, Sabatine MS, Sattar N, Schou M, Hammarstedt A, Sjöstrand M, Langkilde AM, Jhund PS, Solomon SD, McMurray JJV. Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JACC Heart Fail. 2025;13:102393.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 25]  [Cited by in RCA: 19]  [Article Influence: 19.0]  [Reference Citation Analysis (0)]
18.  Lago-Docampo M, Solarat C, Méndez-Martínez L, Baloira A, Valverde D. Common Variation in EDN1 Regulatory Regions Highlights the Role of PPARγ as a Key Regulator of Endothelin in vitro. Front Cardiovasc Med. 2022;9:823133.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 10]  [Article Influence: 2.5]  [Reference Citation Analysis (1)]
19.  Lin H, Lian WS, Chen HH, Lai PF, Cheng CF. Adiponectin ameliorates iron-overload cardiomyopathy through the PPARα-PGC-1-dependent signaling pathway. Mol Pharmacol. 2013;84:275-285.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 24]  [Cited by in RCA: 27]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
20.  Darvish M, Shakoor A, Feyz L, Schaap J, van Mieghem NM, de Boer RA, Brugts JJ, van der Boon RMA. Heart failure: assessment of the global economic burden. Eur Heart J. 2025;46:3069-3078.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 7]  [Cited by in RCA: 58]  [Article Influence: 58.0]  [Reference Citation Analysis (0)]
21.  Chinese Society of Cardiology;  Chinese Medical Association; Chinese College of Cardiovascular Physician;  Chinese Heart Failure Association of Chinese Medical Doctor Association;  Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for the diagnosis and treatment of heart failure 2024]. Zhonghua Xin Xue Guan Bing Za Zhi. 2024;52:235-275.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 35]  [Reference Citation Analysis (1)]
22.  Eity TA, Bhuia MS, Chowdhury R, Ahmmed S, Salehin Sheikh, Akter R, Islam MT. Therapeutic Efficacy of Quercetin and Its Nanoformulation Both the Mono- or Combination Therapies in the Management of Cancer: An Update with Molecular Mechanisms. J Trop Med. 2024;2024:5594462.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 21]  [Reference Citation Analysis (1)]
23.  Naeem H, Shahbaz M, Momal U, Irshad N, Imran M, Hussain M, Yehuala TF, Abdelgawad MA, Mostafa EM, Ghoneim MM, Selim S, Al Jaouni SK, Alsagaby SA, Al Abdulmonem W. Anticancer Potential of Wogonin: A Comprehensive Treatise. Food Sci Nutr. 2025;13:e71128.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 7]  [Reference Citation Analysis (0)]
24.  de Oliveira MR. Mitochondrial physiology and beyond: Mechanistic insights into kaempferol actions. Chem Biol Interact. 2025;421:111743.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
25.  Murphy A, Goldberg S. Mechanical Complications of Myocardial Infarction. Am J Med. 2022;135:1401-1409.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 58]  [Reference Citation Analysis (0)]
26.  Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. Annu Rev Immunol. 2017;35:337-370.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 71]  [Cited by in RCA: 71]  [Article Influence: 7.9]  [Reference Citation Analysis (0)]
27.  O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387:1855-1864.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 22]  [Cited by in RCA: 470]  [Article Influence: 117.5]  [Reference Citation Analysis (3)]
28.  Zhang R, Zhu X, Bai H, Ning K. Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. Front Pharmacol. 2019;10:123.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 992]  [Cited by in RCA: 883]  [Article Influence: 126.1]  [Reference Citation Analysis (7)]
29.  Al Sharif M. Development of mode of action networks related to the potential role of PPARγ in respiratory diseases. Pharmacol Res. 2021;172:105821.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
30.  Beale EG, Forest C, Hammer RE. Regulation of cytosolic phosphoenolpyruvate carboxykinase gene expression in adipocytes. Biochimie. 2003;85:1207-1211.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 25]  [Cited by in RCA: 28]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
31.  Yu S, Meng S, Xiang M, Ma H. Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis. Mol Metab. 2021;53:101257.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 87]  [Cited by in RCA: 196]  [Article Influence: 39.2]  [Reference Citation Analysis (1)]
32.  Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud PD, Yu RT, Alvarez JG, Downes M, Evans RM, Montminy M, Shaw RJ. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell. 2011;145:607-621.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 480]  [Cited by in RCA: 484]  [Article Influence: 32.3]  [Reference Citation Analysis (4)]
33.  De Bels D, Corazza F, Balestra C. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365:1845; author reply 1846.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 26]  [Cited by in RCA: 34]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
34.  Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009;1171:59-76.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 565]  [Cited by in RCA: 559]  [Article Influence: 32.9]  [Reference Citation Analysis (6)]
35.  Brunmeir R, Xu F. Functional Regulation of PPARs through Post-Translational Modifications. Int J Mol Sci. 2018;19:1738.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 101]  [Cited by in RCA: 193]  [Article Influence: 24.1]  [Reference Citation Analysis (0)]
36.  Diaz F, Enríquez JA, Moraes CT. Cells lacking Rieske iron-sulfur protein have a reactive oxygen species-associated decrease in respiratory complexes I and IV. Mol Cell Biol. 2012;32:415-429.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 91]  [Cited by in RCA: 100]  [Article Influence: 6.7]  [Reference Citation Analysis (0)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Cardiac and cardiovascular systems

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade A, Grade B, Grade D

Novelty: Grade A, Grade B, Grade D

Creativity or innovation: Grade A, Grade B, Grade D

Scientific significance: Grade A, Grade B, Grade D

P-Reviewer: Chen Y, Academic Fellow, PhD, China; Lin X, PhD, China S-Editor: Luo ML L-Editor: A P-Editor: Zhang YL

Write to the Help Desk